Ralph N.
- Country
- Germany
- Department
- Abteilung Medizinische Klinik III
Research Overview
- Randomized Phase II Study of Teclistamab + Daratumumab‑Lenalidomide‑Dexamethasone (Tec‑DRd) vs Daratumumab‑Lenalidomide‑Dexamethasone (DVRd) in Transplant‑Eligible NDMM
- Phase III Randomized Trial of High-Dose Chemotherapy with Autologous Stem Cell Transplantation versus R-MP in Elderly Patients with Primary CNS Lymphoma
- Phase 3 Randomized Study of Sonrotoclax and Zanubrutinib Versus Placebo and Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Data & Insights
Has run more than one trial at 23 of 92 partner sites.
Specializations
Hormone Receptor-Positive Breast Cancer
Investigation of endocrine and cyclin‑dependent kinase inhibition strategies in early and advanced disease.
- HR+/HER2- early breast cancer
- Ribociclib combined with endocrine therapy
- Invasive disease‑free survival improvement
- distant disease‑free survival at five years
Focus on personalized endocrine regimens for patients with hormone‑driven tumors.
Diffuse Large B‑Cell Lymphoma Spectrum
Clinical evaluation of combination chemo‑immunotherapy and novel BTK inhibition across diverse DLBCL subtypes.
- DLBCL not otherwise specified
- Primary CNS lymphoma
- Primary cutaneous DLBCL leg type
- EBV+ DLBCL
- High‑grade B‑cell lymphoma with MYC/BCL2 rearrangements
Emphasis on elderly patients and those unsuitable for full‑dose regimens.
BTK Inhibitor Strategies
Assessment of Bruton’s tyrosine kinase blockade combined with reduced‑dose CHOP in older adults.
- Acalabrutinib
- R-miniCHOP
- Progression‑free survival extension
Targets age‑related tolerability challenges in aggressive B‑cell malignancies.
Antibody‑Drug Conjugate Therapy
Evaluation of HER3‑directed antibody‑drug conjugate in hormone‑receptor positive, HER2‑negative metastatic disease.
- Patritumab deruxtecan
- HER3‑DXd
- Overall survival benefit
Provides a non‑chemotherapy option for refractory hormone‑driven breast cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.